-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo
-Results were consistent across both pivotal Phase 3 studies (ELARIS UF-1 and ELARIS UF-2)
- FDA New Drug Application submission anticipated in mid-2019
PR Newswire
NORTH CHICAGO, Ill., Nov. 14, 2018